Sara Lonardi
Sara Lonardi
Istituto Oncologico Veneto IOV-IRCCS, Padova, Italia
Verified email at iov.veneto.it
TitleCited byYear
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial
C Aschele, L Cionini, S Lonardi, C Pinto, S Cordio, G Rosati, S Artale, ...
Journal of clinical oncology 29 (20), 2773-2780, 2011
6582011
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
5482014
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The Lancet Oncology 18 (9), 1182-1191, 2017
4712017
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with …
J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ...
The Lancet Oncology 16 (5), 499-508, 2015
4402015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
4042015
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3162016
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
2302018
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, ...
British journal of cancer 96 (7), 1047, 2007
1862007
A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer
C Aschele, ML Friso, S Pucciarelli, S Lonardi, L Sartor, G Fabris, ...
Annals of oncology 16 (7), 1140-1146, 2005
1652005
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
LC Taieb J1, Tabernero J2, Mini E3, Subtil F4, Folprecht G5, Van Laethem JL6 ...
LANCET ONCOLOGY 15, 862-73, 2014
1532014
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European Journal of Cancer 50 (1), 57-63, 2014
1392014
Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer
C Aschele, S Lonardi, S Monfardini
Cancer treatment reviews 28 (1), 27-47, 2002
1302002
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’trial
R Labianca, A Sobrero, L Isa, E Cortesi, S Barni, D Nicolella, M Aglietta, ...
Annals of oncology 22 (5), 1236-1242, 2010
1022010
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1002015
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost‐benefit analysis while awaiting data on sorafenib safety
A Vitale, ML Volk, D Pastorelli, S Lonardi, F Farinati, P Burra, P Angeli, ...
Hepatology 51 (1), 165-173, 2010
992010
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
982015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481, 2015
932015
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a …
L Fornaro, S Lonardi, G Masi, F Loupakis, F Bergamo, L Salvatore, ...
Annals of oncology 24 (8), 2062-2067, 2013
862013
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
R Velasco, J Bruna, C Briani, AA Argyriou, G Cavaletti, P Alberti, B Frigeni, ...
J Neurol Neurosurg Psychiatry 85 (4), 392-398, 2014
782014
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921, 2015
742015
The system can't perform the operation now. Try again later.
Articles 1–20